Coronary stents

2022

Medtronic starts selling stent for patients with coronary heart disease

On August 25, 2022, Medtronic announced the launch of its new Onyx Frontier DES coronary stent, which is used to treat patients with coronary heart disease caused by a build-up of plaques on the inner surface of the coronary arteries. Read more here.

Russian medical production of stents for cores threatened due to attack by raiders

In June 2022, it became known that Angiolaine had stopped the production of medical devices for cardiac surgery. The company explained the termination of production "certain disagreements between shareholders." Read more here.

2021: Medtronic and Renova joint venture launches production of Translumina coronary stents in Skolkovo

The Russian company Stentex, which transfers the technologies for the production of coronary stents and catheters necessary for the treatment of myocardial infarction and unstable angina, will produce Sirolimus drug-coated coronary stent systems under the Yukon Choice PC and Yukon Chrome PC brand, which are developed by the German-Indian company Translumina. This became known at the end of July 2021. Read more here.

2019

Ministry of Health decided to digitally label diapers and coronary stents

In December 2019, it became about the digital labeling of medical devices planned by the Government of the Russian Federation. From February 1, 2020 to September 1, 2021, it is planned to conduct a pilot project to control the supply of diapers and coronary stents. Read more here.

Stents in the heart are no better than drugs

In mid-November 2019, the results of a global study were published, which showed that in many patients with severe but stable coronary heart disease, regular medication and a healthy lifestyle prevent heart attack and death from heart disease no less effectively than invasive procedures with stent placement.

A government-supported study questioned the concept that invasive procedures to restore normal blood flow in patients with stable coronary heart disease are more effective than conservative treatment with aspirin, lipid-lowering and antihypertensive agents. Scientists have concluded that stenting or bypass grafting is far from always necessary for a patient with a stable disease. According to experts, many cardiologists do not want to change their tactics in part because patients with stents usually feel relief quickly, while with conservative therapy, changes occur gradually, and the patient barely feels them.

Medication and a healthy lifestyle prevent heart attack and death from heart disease no less effectively than invasive procedures with stent placement.

For those who experience little or no chest pain, immediate stenting will play no role... But with myocardial infarction, stents save lives.

The study covered 37 countries and included 5179 participants with moderate to severe but stable cardiac ischemia. Half of the participants received only drugs and lifestyle recommendations over a four-year period, while the other half underwent surgeries in addition to drug therapy. More than $100 million was spent on the study.^[1]

Medtronic and Boston Scientific continue to sell stents that are dangerous to humans

At the beginning of January 2019, Medtronic and Boston Scientific continue to sell stents coated with paclitaxel, despite the fact that a month earlier a study was published indicating an association between the use of devices and an increased mortality rate. Read more here.

2017: Lower bench prices in India

In mid-September 2017, it became known about a significant decrease in prices for coronary stents in India, which had a positive effect on the business of local manufacturers, which cannot be said about foreign companies such as Medtronic and Abbott.

According to The Economic Times (ET), the Indian government has reduced the maximum cost of stents by more than 80%. This has led to increased sales of equipment from local vendors including Sahajanand Medical Technologies (SMT), Translumina Therapeutics and Meril Life Sciences, which jointly control about 30% of the Indian stent market.

Coronary stent

Thanks to restrictive measures of the authorities, local manufacturers expect to occupy 60% of the market in 2017, the volume of which, however, can be reduced to 12 billion rupees ($187.3 million) from 15 billion rupees (about $234 million) in 2016. This decline will be the result of cheaper products, Rajiv Nath, coordinator of the Association of Indian Medical Device Industry (AiMeD), told ET.

He did not disclose the dynamics of stent sales after changing the price threshold. Sources of the publication speak of a rise of 30-50%.

At the end of 2017, SMT, Translumina and Meril expect to bring their share in the Indian coronary stent market to 35% due to "confusion and panic," which appeared after international companies were forced to curtail sales of new products in the country, said the head of one of the mentioned Indian companies.

Abbott said that the reduction in maximum prices prevents the company from selling new stents in India, since their cost is higher than the prices at which devices can be sold. Medtronic and Boston Scientific have also approached Indian pharmaceutical market regulator NPPA over the recall of new products.^[2]

Notes